Immunic has been granted a patent for a method to treat multiple sclerosis using the DHODH inhibitor vidofludimus. The method involves administering a daily dose of 10-45 mg of the compound to alleviate symptoms of relapsing-remitting multiple sclerosis in human patients. GlobalData’s report on Immunic gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Immunic Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Immunic, Wearable breast pumps was a key innovation area identified from patents. Immunic's grant share as of February 2024 was 41%. Grant share is based on the ratio of number of grants to total number of patents.

Treatment of relapsing-remitting multiple sclerosis with vidofludimus

Source: United States Patent and Trademark Office (USPTO). Credit: Immunic Inc

A recently granted patent (Publication Number: US11877994B2) discloses a method for treating relapsing-remitting multiple sclerosis in human patients. The method involves orally administering a specific compound, 2-({3-fluoro-3'-methoxy-[1,1'-biphenyl]-4-yl}carbamoyl)cyclopent-1-ene-1-carboxylic acid or its pharmaceutically acceptable salt or solvate, at a daily dose ranging from 10 mg to 45 mg. This treatment aims to alleviate symptoms associated with the condition and improve various aspects such as reducing relapse rate, disability accumulation, fatigue levels, and MRI-monitored disease activity, among others.

Furthermore, the patent claims that the administration of the compound can be effective as monotherapy or as adjunct therapy with other multiple sclerosis treatments like interferon beta, glatiramer acetate, or ocrelizumab. The method is also said to provide neuroprotection to patients by increasing the time to confirmed disease progression, reducing brain atrophy, and improving overall health. The compound can be administered in the form of a tablet or capsule, with the daily dose calculated based on the weight of the specific compound, offering a potentially promising approach to managing relapsing-remitting multiple sclerosis.

To know more about GlobalData’s detailed insights on Immunic, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies